With Entresto sales slowly climbing to $53m in third quarter, Novartis releases data supporting value of heart failure drug in preventing costly hospitalizations at the annual American Heart Association meeting.
As part of a package supporting its sluggish selling heart failure drug Entresto with payers,Novartis AG released additional data showing that the drug reduces the rate of heart failure hospitalizations and deaths related to the condition compared to the standard of care enalapril.
The FDA's approval of Entresto, which combines the neprilysin inhibitor sacubitril with the angiotensin receptor blocker valsartan, in July 2015...
The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.
Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.
Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
The Belgian drugmaker is boosting its biologics capacity over the pond.
